Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Prenatal > Hydrops Fetalis Precision Panel

Hydrops Fetalis Precision Panel

Hydrops fetalis or fetal hydrops is a lethal fetal condition defined as abnormal accumulation of fluid in two or more fetal compartments presenting as ascites, pleural effusion, pericardial effusion and skin edema.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Hydrops fetalis or fetal hydrops is a lethal fetal condition defined as abnormal accumulation of fluid in two or more fetal compartments presenting as ascites, pleural effusion, pericardial effusion and skin edema. It may also be associated with polyhydramnios and placental edema. Hydrops is usually detected using ultrasound in the first or second trimester of pregnancy. The etiology can be immune or nonimmune. Immune hydrops fetalis is due to Rhesus (Rh) or ABO incompatibility and other blood group antibodies causing hemolytic disease of the newborn. Nonimmune hydrops fetalis can be divided as fetal, maternal, placental and idiopathic. A wide spectrum of genetic causes may lead to nonimmune hydrops fetalis (NIHF), and so a phenotypic and genetic evaluation are necessary to determine the underlying etiology. The mode of inheritance is generally autosomal recessive and autosomal dominant, although several X-linked related pathologies have been identified. 

  • The Igenomix Hydrops Fetalis Syndrome Precision Panel can be used to make a directed and accurate diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

  • The Igenomix Hydrops Fetalis Syndrome Precision Panel is indicated for those patients with ultrasound findings suggestive of hydrops fetalis or with the following manifestations: 
    • Twin pregnancy 
    • Previous fetal death 
    • Prolonged or excessive jaundice in siblings as newborns 
    • Family history of genetic disorders, chromosomal abnormalitiesor metabolic diseases 
    • Polyhydramnios or oligohydramnios 
    • Evidence of viral illness in mother or fetus 
    • Decreased fetal movements  
    • Fetal tachyarrythmias 
    • Maternal history of: Rh negative blood type, known presence of isoimmune blood group antibodies, illicit drug use, collagen vascular disease, blunt abdominal trauma, coagulopathy, hemoglobinopathy etc 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of treatment in the form early referral to a high-risk center, multidisciplinary counselling and close coordination between obstetric and neonatal specialists or early invasive fetal treatment. 
  • Risk assessment of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation. 

Genes & Diseases

Methodology

References

See scientific referrals

Waring, G. J., Splitt, M., & Robson, S. C. (2019). Fetal hydrops: diagnosis and prognosis. Archives of disease in childhood, 104(3), 209–210. https://doi.org/10.1136/archdischild-2018-315777 

Mardy, A. H., Chetty, S. P., Norton, M. E., & Sparks, T. N. (2019). A system-based approach to the genetic etiologies of non-immune hydrops fetalis. Prenatal diagnosis, 39(9), 732–750. https://doi.org/10.1002/pd.5479 

Bellini, C., & Hennekam, R. (2012). Non-immune hydrops fetalis: A short review of etiology and pathophysiology. American Journal Of Medical Genetics Part A, 158A(3), 597-605. doi: 10.1002/ajmg.a.34438 

Sparks, T. N., Thao, K., Lianoglou, B. R., Boe, N. M., Bruce, K. G., Datkhaeva, I., Field, N. T., Fratto, V. M., Jolley, J., Laurent, L. C., Mardy, A. H., Murphy, A. M., Ngan, E., Rangwala, N., Rottkamp, C., Wilson, L., Wu, E., Uy, C. C., Valdez Lopez, P., Norton, M. E., … University of California Fetal–Maternal Consortium (UCfC) (2019). Nonimmune hydrops fetalis: identifying the underlying genetic etiology. Genetics in medicine : official journal of the American College of Medical Genetics, 21(6), 1339–1344. https://doi.org/10.1038/s41436-018-0352-6 

Désilets, V., Audibert, F., Wilson, R., Audibert, F., Brock, J., & Carroll, J. et al. (2013). Investigation and Management of Non-immune Fetal Hydrops. Journal Of Obstetrics And Gynaecology Canada, 35(10), 923-936. doi: 10.1016/s1701-2163(15)30816-1 

Jauniaux E. (1997). Diagnosis and management of early non-immune hydrops fetalis. Prenatal diagnosis, 17(13), 1261–1268. https://doi.org/10.1002/(sici)1097-0223(199712)17:13<1261::aid-pd292>3.0.co;2-c 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information